AIM ImmunoTech Inc is trading 13.3% down at $0.72 in pre-market, extending a sharp pullback from its recent speculative surge.
- The stock more than doubled late last week on excitement surrounding its pancreatic cancer trial results.
- Subsequent sessions have seen consistent profit-taking and volatility as traders unwind short-term gains and reassess the risk around early-stage clinical data.